All posts by medical

The Challenges of Studying Marijuanas Effects on the Heart and Brain – Neuroscience News

Summary: Researchers identify problem areas they face in studying the effects of cannabis on the brain and heart function.

Source: American Heart Association

Over the past decade, marijuana use, both recreational and medicinal, has grown as state governments across the U.S. have legalized its use. But while it might be legal for adults to light up, the question of whether it is harmful or helpful in many cases remains unanswered.

Researchers say the truth is complicated.

Though it has been studied for decades, much remains unknown about how marijuana, or cannabis, affects heart and brain health. And there are significant challenges to finding clear answers.

The evidence that has been emerging from animal models show ramifications in the brain and in the heart, but the data for humans is more murky, said Dr. Fernando Daniel Testai, a neurologist at the University of Chicago Department of Neurology and Rehabilitation. Testai was lead author on an American Heart Associationscientific statementlast year that detailed whats known, and not known, about marijuanas effects on brain health.

So many things factor into the equation, said Staci Gruber, an associate professor of psychiatry at Harvard Medical School in Boston. She oversees the Marijuana Investigations for Neuroscientific Discovery (MIND) program at McLean Hospital in Belmont, Massachusetts, which studies the effects of medical marijuana on clinical and cognitive measures, as well as brain structure and function and quality of life.

Differences in how people use marijuana, concentrations of the products they use, the active ingredients they contain, how often they use them and for how long, as well as age all may play a role in determining how health is affected, Gruber said. Its up to researchers to drill down in each of these areas, but legal, ethical and other hurdles make it difficult to do so.

More than 48 million people in the U.S. over the age of 12 reported using marijuana in 2019, according to theSubstance Abuse and Mental Health Administration. Thats roughly 18% of the population, which is up from 11% two decades ago.

Also known as pot or weed, marijuana can be used recreationally or formedicinal purposes, such as to reduce nausea or ease chronic pain in people with cancer. It can be smoked in cigarette form or through pipes or water pipes, vaped, or infused into baked goods, gummy candies or drinks.

Its compounds can be extracted to make oils and concentrates, which can also be vaped or smoked.Little is knownabout the safety of one method compared to another, though there is evidence the combustion from smoking marijuana can be harmful.

Gruber said some of the confusion stems from what people mean when they use the word marijuana. Marijuana refers to the dried flowers, leaves, stems and seeds of the cannabis plant, which contains more than 100 chemical compounds.

The two most recognized are tetrahydrocannabinolTHCresponsible for the plants mind-altering effects, and cannabidiolCBDwhich does not produce a high but has been used to treat pediatric seizure disorders, anxiety, pain and inflammation.

We often use the terms marijuana or cannabis to describe anything that comes from the plant, but different compounds from the plant have different effects, Gruber said.

When discussing health impacts, its also important to distinguish between recreational and medicinal use, she said. Recreational users tend to look for high THC content in the products they use. Medical users may or may not. They dont typically want to get high, but want to alleviate symptoms so they can do everyday things like go to the store and remember why they are there.

Some studies suggestchronic, heavy recreational use can harm cognitive functionespecially if that use begins during adolescence. But research shows adult medical cannabis patients may experience some cognitive benefits. Gruber was the senior author of astudy published 2018 in theFrontiers of Pharmacologyjournalthat showed people who used medical cannabis experienced improvements in executive function over time, with no deficits in verbal learning or memory.

There also are differences in how different types of use affect heart health.

Though the high levels of THC exposure from recreational usemay cause a rise in blood pressure, said Gruber, astudy last year in Israelfound people age 60 and older who used medical marijuana for three months had a reduction inblood pressure.

A 2020scientific statementfrom the AHA saidobservational studieshave linkedmarijuana useto an increased risk of heart attacks, atrial fibrillation and heart failure, but acknowledged its impact on the heart and blood vessels was not well understood due to a lack of adequate research.

A study that directly compares the effects of medical marijuana use to recreational use would help, Testai said. As would a clearer definition of what chronic, heavy recreational use really means.

Most studies measure exposure to marijuana based on self-reported use, he said. Theres no objective data for how much people are consuming.

Another challenge is people who use it recreationally may use other drugs or substances, such as cigarettes or other mind-altering drugs. That makes it difficult to tease out which impacts come from which substances, Testai said.

How often a person uses marijuana, how much they use and for how long matters, Gruber said. For example, people may initially experience a rapid heart rate, called tachycardia, from products containing THC. But consistent use may result in tolerance to that effect, often after a few days or weeks.

In clinical studies, researchers measure and control what people are consuming. But because the federal government still classifies marijuana as a schedule 1 substance, meaning it is considered to have a high potential for abuse, researchers face tough restrictions on the products they can give study participants.

The National Institute on Drug Abuse Drug Supply Program provides marijuana for research purposes, Gruber said. But research-grade marijuana isnt what people are consuming in their homes.

Unlike alcohol, which is pretty straightforward, cannabis is many different things, she said. She asks people who use recreational marijuana in her observational studies to submit samples of the products they use most often so they can be analyzed to better measure whats going into their bodies.

Age also plays an important role, Gruber said. Evidence suggests using marijuana during key periods of brain development may harm cognition more than it would if use began in adulthood.

Testai said researchers face another obstacle: the inability to assign a control group to placebo.

The most fundamental or clear way to practice research is a randomized study with placebo, he said. But with marijuana, there is no way you can actually mask its effect. Doing high-quality research in this field is confounded by the waymarijuanaworks, not to mention the ethics.

Until theres a better solution, said Gruber, researchers have to be creative thinkers. We have to try to capture observational data as closely and rigorously as we can as well as conduct empirically sound clinical trials.

Author: Laura WilliamsonSource: American Heart AssociationContact: Laura Williamson American Heart AssociationImage: The image is in the public domain

See the article here:
The Challenges of Studying Marijuanas Effects on the Heart and Brain - Neuroscience News

Insights on the Mental Health Apps Global Market to 2027: Featuring Sanvello Health, Flow Neuroscience and Youper Among Others – GlobeNewswire

Dublin, April 21, 2022 (GLOBE NEWSWIRE) -- The "Global Mental Health Apps Market Size, Share & Industry Trends Analysis Report By Application, By Platform Type (iOS, Android, and Others), By Regional Outlook and Forecast, 2021-2027" report has been added to ResearchAndMarkets.com's offering.

The Global Mental Health Apps Market size is expected to reach $10.2 billion by 2027, rising at a market growth of 16.3% CAGR during the forecast period.

The market is rising because individuals become more aware of the significance of mental health and as a result of the debut of several mental wellness applications. The advent of significant health campaigns such as the Campaign Against Living Miserably (CALM) to promote awareness about mental health, as well as the rising use of connected gadgets among the youthful population, is driving up market value.

Furthermore, poor work-life balance and eating habits, social isolation, hectic schedules, and relationship issues are all key factors that are raising the incidence of mental illness among people all over the world, particularly in developed and emerging nations. Moreover, it is expected that increased awareness among people in developing economies, as well as the creation of updated and advanced featured applications, is expected to provide prospective prospects over the forecast period.

Therapy applications were already gaining traction among people dealing with issues ranging from stress to serious mental disease when the COVID-19 outbreak struck. When offices turned virtual, they carved out a niche for themselves in the mental health industry. While certain apps, such as Talkspace and Betterhelp, pair you with a certified therapist, a large chunk of the industry has gone completely humanless. Friendly chatbots provide cognitive behavioural therapy; mood trackers remind bipolar disorder patients to keep track of their mood; and apps for treating post-traumatic stress disorder claim to assist people to get over acute bouts by guiding them through deep breathing exercises.

COVID-19 Impact AnalysisThe COVID-19 pandemic resulted in a spike in mental health app downloads as well as greater awareness of mental health as a serious concern. As a result, the digital health and mobile health sectors have shown significant growth potential. According to ORCHA (Organization for the Review of Care and Health Applications) data, mental health app downloads in the United Kingdom climbed by about 200 percent from summer 2019 to summer 2020.

Due to the many advantages offered by these apps in treating mental health conditions like as stress, sadness, and anxiety, the market for mental health apps saw a rise in adoption during the COVID-19 pandemic. As per Sensor Tower statistics, the top mental wellness apps saw a combined download increase of about 2 million in April 2020 compared to January.

Market Growth Factors:

High inclination towards virtual therapiesFor persons suffering from depression, there are literally thousands of apps available. Some are based on exchanging messages or making phone calls with doctors, while others provide recommendations, self-guided mood training programmes, and gamification components. MoodTools, an anti-depression app, treats depression carefully and has a suicide safety plan in place in the event of a crisis. There are additional apps for treating diseases like schizophrenia and psychoses, in addition to depression apps. Doctors, on the other hand, argue that apps for people with psychological illnesses are best used as a supplement to regular therapy; unlike apps for mentally healthy people, applications for persons with psychological disorders must include doctors.

Increasing stress level among individualsPeople's or society's stress levels are rising as a result of causes such as substance addiction, increased mental health awareness in recent years, and fewer social connections. In addition, over time, the use of advanced linked technologies such as physician-recommended mental health apps, wearables, and self-assessment awareness gadgets has grown. As a result, demand for mental health apps is predicted to increase in recent years. Psychotherapists, other doctors, psychiatrists, and clinical psychologists can use mental apps to examine and monitor their patients' mental health. As a result, the market for mental health applications is fueled by the adoption of such apps by experts.

Market Restraining Factors

Privacy and research concernsAlthough there is research on using mobile apps in conjunction with therapy, there is little research about how these apps are developed, with one exception: if the apps are produced by the federal government, such as the Substance Abuse and Mental Health Administration (SAMHSA) or the US Department of Veteran's Affairs (VA)/Department of Defense (DOD), they usually include app development information. There are two types of mental health apps for mobile devices: passive and active. Active apps necessitate direct patient input, like the completion of mood logs, self-symptom ratings, and the recording of personal experiences. Without the patient or provider's knowledge, passive apps can access information and collect data using smartphone functions like GPS. Though it may be advantageous, some people may object to the possible invasion of privacy that such data collection entails.

Application OutlookBased on Application, the market is segmented into Depression & Anxiety Management, Meditation Management, Stress Management, Wellness Management, and Others. The stress management segment witnessed a promising revenue share in the mental health apps market in 2020. The increasing prevalence of stress and related diseases, as well as the growing usage of applications that aid in stress reduction and management, are driving the segment's rise over the forecast period.

Platform Type OutlookBased on Platform Type, the market is segmented into iOS, Android, and Others. In 2020, the iOS segment procured the highest revenue share in the mental health apps market. The growing acceptance of iOS among customers can be linked to the rise of the iOS category. The market share of iOS in the United Kingdom climbed from 47 percent in Q3 2020 to 51.6 percent in Q3 2021, according to data published by Business of Apps in 2021. As a result, such examples show that the segment will grow in the next years.

Regional OutlookBased on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America emerged as the leading region in the mental health apps market with the maximum revenue share in 2020. The market is being fueled by prominent factors such as the increasing adoption of smartphones, advancements in coverage networks, and increased penetration of the internet and social media. Smartphone usage in the North American region was around 80% in 2020, according to the GSMA's The Mobile Economy Report 2021, and is anticipated to reach 85 percent by 2025.

Recent Strategies Deployed in Mental Health Apps Market

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/u6thhb

View original post here:
Insights on the Mental Health Apps Global Market to 2027: Featuring Sanvello Health, Flow Neuroscience and Youper Among Others - GlobeNewswire

Artificial Intelligence to Assess Dementia Risk and Enhance the Effectiveness of Depression Treatments – Neuroscience News

Summary: Using MEG data, a new AI algorithm called AI-MIND is able to assess dementia risk and the potential effectiveness of treatments for depression, researchers say.

Source: Aalto University

The human brain consists of some 86 billion neurons, nerve cells that process and convey information through electrical nerve impulses.

Thats why measuring neural electrical activity is often the best way to study the brain, says Hanna Renvall. She is Aalto University and HUS Helsinki University Hospital Assistant Professor in Translational Brain Imaging and heads the HUS BioMag Laboratory.

Electroencephalography, or EEG, is the most used brain imaging technique in the world. Renvalls favorite, however, is magnetoencephalography or MEG, which measures the magnetic fields generated by the brains electrical activity.

MEG signals are easier to interpret than EEG because the skull and other tissues dont distort magnetic fields as much. This is precisely what makes the technique so great, Renvall explains.

MEG can locate the active part of the brain with much greater accuracy, at times achieving millimeter-scale precision.

An MEG device looks a lot like bonnet hairdryers found in hair salons. The SQUID sensors that perform the measurements are concealed and effectively insulated inside the bonnet because they only function at truly freezing temperatures, close to absolute zero.

The worlds first whole-head MEG device was built by a company that emerged from Helsinki University of Technologys Low Temperature Laboratoryand is now the leading equipment manufacturer in this field.

MEG plays a major role in the European Unions new AI-Mind project, whose Finnish contributors are Aalto and HUS. The goal of the 14-million project is to learn ways to identify those patients, whose dementia could be delayed or even prevented.

For this to happen, neuroscience and neurotechnology need help from artificial intelligence experts.

Fingerprinting the brain

Dementia is a broad-reaching neural function disorder that significantly erodes the sufferers ability to cope with everyday life. Some 10 million people are afflicted in Europe, and as the population ages this number is growing. The most common illness that causes dementia is Alzheimers disease, which is diagnosed in 7080% of dementia patients.

Researchers believe that communication between neurons begins to deteriorate well before the initial clinical symptoms of dementia present themselves. This can be seen in MEG dataif you know what to look for.

MEG is at its strongest when measuring the brains response to stimuli like speech and touch that occur at specific moments and are repetitive.

Interpreting resting-state measurements is considerably more complex.

Thats why the AI-Mind project uses a tool referred to as the fingerprint of the brain. It was created when Renvall and Professor Riitta Salmelin and her colleagues began to investigate whether MEG measurements could detect a persons genotype.

More than 100 sibling pairs took part in the study that sat subjects in an MEG, first for a couple of minutes with their eyes closed and then for a couple of minutes with their eyes open. They also submitted blood samples for a simple genetic analysis.

When researchers compared the graphs and genetic markers, they noticed that, even though there was substantial variance between individuals, siblings graphs were similar.

Next, Aalto University Artificial Intelligence Professor Samuel Kaskis group tested whether a computer could learn to identify graph sections that were as similar as possible between siblings while also being maximally different when compared to other test subjects.

The machine did itand more, surprisingly.

It learned to distinguish the individual perfectly based on just the graphs, irrespective of whether the imaging had been performed with the test subjects eyes open or closed, Hanna Renvall says.

For humans, graphs taken with eyes closed or open look very different, but the machine could identify their individual features. Were extremely excited about this brain fingerprinting and are now thinking about how we could teach the machine to recognize neural network deterioration in a similar manner.

Risk screening in one week

A large share of dementia patients are diagnosed only after the disorder has already progressed, which explains why treatments tend to focus on managing late-stage symptoms.

Earlier research has, however, demonstrated that many patients experience cognitive deterioration, such as memory and thought disorders, for years before their diagnosis.

One objective of the AI-Mind project is to learn ways to screen individuals with a significantly higher risk of developing memory disorders in the next few years from the larger group of those suffering from mild cognitive deterioration.

Researchers plan to image 1,000 people from around Europe who are deemed at risk of developing memory disorders and analyze how their neural signals differ from people free from cognitive deterioration. AI will then couple their brain imaging data with cognitive test results and genetic biomarkers.

Researchers believe this method could identify a heightened dementia risk in as little as a week.

If people know about their risk in time, it can have a dramatic motivating effect, says Renvall, who has years of experience of treating patients as a neurologist.

Lifestyle changes like a healthier diet, exercise, treating cardiovascular diseases and cognitive rehabilitation can significantly slow the progression of memory disorders.

Better managing risk factors can give the patient many more good years, which is tremendously meaningful for individuals, their loved ones and society, as well, Renvall says.

Identifying at-risk individuals will also be key when the first drugs that slow disease progression come on the market, perhaps in the next few years. Renvall says it will be a momentous event, as the medicinal treatment of memory disorders has not seen any substantial progress in the last two decades.

The new pharmaceuticals will not suit everybody, however.

These drugs are quite powerful, as are their side effectsthats why we need to identify the people who can benefit from them the most, Renvall emphasizes.

Zapping the brain

Brain activity involves electric currents, which generate magnetic fields that can be measured from outside the skull.

The process also works in the other direction, the principle on whichtranscranial magnetic stimulation(TMS) is based. In TMS treatments, a coil is placed on the head to produce a powerful magnetic field that reaches the brain through skin and bone, without losing strength. Themagnetic fieldpulse causes a short, weak electric field in the brain that affects neuron activity.

It sounds wild, but its completely safe, says Professor of Applied Physics Risto Ilmoniemi, who has been developing and using TMS for decades.

The strength of the electric field is comparable to the brains own electric fields. The patient feels the stimulation, which is delivered in pulses, as light taps on their skin.

Magnetic stimulation is used to treatsevere depressionand neuropathic pain. At least 200 million people around the world suffer from severe depression, while neuropathic pain is prevalent among spinal injury patients, diabetics and multiple sclerosis sufferers. Pharmaceuticals provide adequate relief to only half of all depression patients; this share is just 30% in the case of neuropathic pain sufferers.

How frequently pulses are given is based on the illness being treated. For depression, inter-neuron communication is stimulated with high-frequency pulse series, while less frequent pulses calm patients neurons for neuropathic pain relief.

Stimulation is administered to the part of the brain where, according to the latest medical science, the neurons tied to the illness being treated are located.

About half of treated patients receive significant relief from magnetic stimulation. Ilmoniemi believes this could be much higherwith more coils and the help of algorithms.

One-note clanger to concert virtuoso

In 2018, the ConnectToBrain research project headed by Ilmoniemi was granted 10 million in European Research Council Synergy funding, the first time that synergy funds were awarded to a project steered by a Finnish university. Top experts in the field from Germany and Italy are also involved.

The goal of the project is to radically improve magnetic stimulation in two ways: by building a magnetic stimulation device with up to 50 coils and by developing algorithms to automatically control the stimulation in real time, based on EEG feedback.

Ilmoniemi looks to the world of music for a comparison.

The difference between the new technology and the old is analogous to a concert pianist playing two-handed, continuously fine-tuning their performance based on what they hear, rather than hitting a single key while wearing hearing protection.

Researchers have already used a two-coil device to demonstrate that an algorithm can steer stimulation in the right direction ten times faster than even the most experienced expert. This is just the beginning.

A five-coil device completed last year covers an area of ten square centimeters of cortex at a time. A 50-coil system would cover both cerebral hemispheres.

Building this kind of device involves many technical challenges. Getting all these coils to fit around the head is no easy task, nor is safely producing the strong currents required.

Even once these issues are resolved, the hardest question remains: how can we treat the brain in the best possible way?

What kind of information does the algorithm need? What data should instruct its learning? It is an enormous challenge for us and our collaborators, Ilmoniemi says thoughtfully.

The project aims to build one magnetic stimulation device for Aalto, another for the University of Tbingen in Germany and a third for the University of Chieti-Pescara in Italy. The researchers hope that, in the future, there will be thousands of such devices in operation around the world.

The more patient data is accumulated, the better the algorithms can learn and the more effective the treatments will become.

Quantum optics sensors could revolutionize how we read neural signals

Professor Lauri Parkkonens working group is developing a new kind of MEG device that adapts to the head size and shape and utilizes sensors based onquantum optics. Unlike the SQUID sensors currently employed in MEG, they do not need to be encased in a thick layer of insulation, enabling measurements to be taken closer to the scalp surface. This makes it easier to perform precise measurements on children and babies especially.

The work has progressed at a brisk pace and yielded promising results: measurements made with optical sensors are already approaching the spatial accuracy of measurements made inside the cranium.

Parkkonen believes that a MEG system based on optical sensors could also be somewhat cheaper and more compact and thus easier to place than traditional devices; such a MEG system could utilize a person-sized magnetic shield instead of a large shielded room as the conventional MEG systems do.

This would bring it into reach of more researchers and hospitals.

Author: Minna HlttSource: Aalto UniversityContact: Minna Hltt Aalto UniversityImage: The image is in the public domain

Excerpt from:
Artificial Intelligence to Assess Dementia Risk and Enhance the Effectiveness of Depression Treatments - Neuroscience News

Measuring Natures Effects on Physical and Mental Health – Neuroscience News

Summary: Spending time enjoying the great outdoors improves both physical and mental health. Researchers say more interventions need to be taken to get people to spend time enjoying nature.

Source: Texas A&M

A study recently published inBMC Psychologyoutlines two scales created to measure factors related to time spent in nature, a first step in exploring how this affects health and well-being.

The scales were developed by a multidisciplinary team led byJay Maddock, professor in the Department of Environmental and Occupational Health at theTexas A&M University School of Public Health.

A body of evidence has shown that time spent in nature, or TSN, is associated with physical and mental health, yet most American adults spend very little time in green or natural spaces. Two strong predictors of health behaviors are self-efficacy and intentions.

However, scales to measure these factors have not yet been developed and are needed to create effective, evidence-based interventions to increase TSN.

The researchers used a nine-phase procedure to construct, refine and test the scales. The first phase identified self-efficacy and intentions as the factors that would be measured by the scales. Self-efficacy was defined as a persons confidence in his or her ability to take action and to persist in that action despite obstacles or challenges pertaining to spending time in nature.

Next, Intentions were defined as planning to engage in certain nature-related behaviors over the next three months. The first phase also involved initial generation of items to include in a survey to measure these factors.

Respondents were asked how confident they were that they could spend at least two hours per week in green or natural spaces under conditions including weather, stress, accessibility, scheduling or costs. They also were asked if they intended to participate in nature-related activities such as going outdoors, hiking or visiting parks in the next three months.

The survey was administered to a nationwide sample of more than 2,000 adults.

Spending more time in nature was found to correlate with both self-efficacy and intentions, suggesting that future interventions to improve TSN should have increasing confidence to spend time in nature as a goal.

Both factors negatively correlated with age, indicating diminishing confidence that could be related to mobility or safety concerns that increase as adults age.

Male respondents had higher self-efficacy than female respondents, a finding that agrees with other research showing that women are less likely to participate in recreational activities in nature despite showing a preference for doing so.

Development of the scales is just the first step of what the researchers hope will be a series of studies with the ultimate goal of finding ways to improve health and well-being through increased TSN.

Were working on developing a whole suite of measures, Maddock said. Once those are done, were going to be looking to develop theory-based interventions to increase time spent in nature.

Author: Rae Lynn MitchellSource: Texas A&MContact: Rae Lynn Mitchell Texas A&MImage: The image is in the public domain

Original Research: Open access.Development and validation of self-efficacy and intention measures for spending time in nature by Jay Maddock et al. BMC Psychology

Abstract

Development and validation of self-efficacy and intention measures for spending time in nature

The purpose of this study was to develop and evaluate the reliability and validity of self-efficacy and intentions measures for time spent in nature (TSN). TSN is related to improvement in psychological well-being and health, yet most American adults spend very little time in such settings. Theory-based interventions have been effective in increasing physical activity, a related behavior, and may be one mechanism to increase TSN. Self-efficacy and intentions have been shown to be strong predictors of health behaviors and are used across several theories. However, scales to measure these factors have not yet been developed and are needed to facilitate effective interventions.

TSN self-efficacy and intentions scales were developed using a sequential nine-step procedure: identification of the domain and item generation; content validity; pre-testing of questions; sampling and survey administration; item reduction; extraction of factors; tests of dimensionality; tests of reliability; and tests of validity. The 14-member multidisciplinary, researcher and practitioner investigative team generated 50 unique items for self-efficacy and 24 unique items for intentions. After subjecting items to content validity and pre-testing, item sets were reduced to 21 assessing self-efficacy and nine assessing intentions. A nationwide sample of 2109 adult participants (49.7% female, Mean Age=58.1; 59.8% White, 18.4% Hispanic, 13.3% Black) answered these items via an on-line survey.

Using split-half measures, principal components analysis indicated a one-factor solution for both scales. The factor structure was upheld in confirmatory factor analyses and had high internal consistency (=.93 self-efficacy; .91 intentions). The scales were moderately correlated with each other (r=.56,p<.001) and were strongly related to TSN with large effect sizes (eta2>.20).

The study resulted in reliable and valid self-efficacy (14 items) and intentions (8 items) scales that can be used to develop future theory-based interventions to increase TSN and thereby improve population health.

Continued here:
Measuring Natures Effects on Physical and Mental Health - Neuroscience News

Windows to the Soul: Pupils Reveal Aphantasia The Absence of Visual Imagination – Neuroscience News

Summary: People who experience visual imagination have pupillary responses that optimize the amount of light hitting the retina and change in response to imagined items. This pupillary response does not occur in those with aphantasia.

Source: University of New South Wales

The study, led by researchers from UNSW Sydney andpublished ineLife, found that the pupils of people with aphantasia did not respond when asked to imagine dark and light objects, while thosewithoutaphantasiadid.

To first gauge the pupillary reflex of non-aphantasic people, the researchers sought 42 study participants, self-reported as having a visual imagination, and fitted them with glasses to track their eye movements and pupil sizes.

Participants were then exposed to bright or dark shapes against a grey background, which predictably evoked pupillary constriction in response to bright shapes (comparable to looking up at a bright sky) and pupillary dilation in response to dark shapes (after switching a light off).

Next, to test visual imagery the minds capacity to visualise objects participants were asked to simply imagine those same light or dark shapes (with their eyes open, for their pupils to be tracked) and subsequently report the vividness of that imagery.

The researchers found that even in response toimaginedbright and dark shapes, the participants pupils still constricted and dilated appropriately, a pupillary response that was larger in those reporting greater imagery vividness.

The pupillary reflex is an adaption that optimises the amount of light hitting the retina, says Professor Joel Pearson, senior author on the paper.

And while it was already known that imagined objects can evoke so-called endogenous changes in pupil size, we were surprised to see more dramatic changes in those reporting more vivid imagery. This really is the first biological, objective test for imagery vividness.

Testing for a lack of imagination

Finally, with the link between visual imagery and pupillary response established, the researchers sought to test the effect in aphantasic individuals. The researchers repeated the study with 18 participants self-reporting aphantasia.

Exposing participants to bright and dark shapes, the researchers found that aphantasic individuals exhibited the same pupillary response as the general population: constriction to bright, dilation to dark.

However, during the studys second component where participants were asked to visualise those same shapes, the pupillary response of aphantasic individuals did not significantly differ in response to imagined dark versus imagined bright objects.

One of the problems with many existing methods to measure imagery is that they are subjective, that is to say they rely on people being able to accurately assess their own imagery. Our results show an exciting new objective method to measure visual imagery, says Prof Pearson, and the first physiological evidence of aphantasia. With over 1.3 million Australians thought to have aphantasia, and 400 million more internationally, we are now close to an objective physiological test, like a blood test, to see if someone truly has it.

To ensure the aphantasic participants were really attempting imagery, the researchers included a further experimental condition, requesting aphantasic individuals to visualise four shapes, instead of one.

While the pupils of those with aphantasia showed no difference when imagining light versus dark objects, they did show a difference imagining one versus four objects, suggesting more mental effort, thereby negating an explanation of non-participation by aphantasic individuals.

Our pupils are known to get larger when we are doing a more difficult task, says Lachlan Kay, PhD candidate in the Future Minds Lab, UNSW.

Imagining four objects simultaneously is more difficult than imagining just one. The pupils of those with aphantasia dilated when they imagined four shapes compared to one, but did not change based on the whether the shapes were bright or dark. This indicated that the participants with aphantasia were indeed trying to imagine in this experiment, just not in a visual way.

The aphantasic pupil response to the four objects condition is also a really exciting finding, adds Prof Pearson, because for the first time we have strong biological evidence that those with aphantasia are really trying to create a mental image, putting to rest claims that they may simply not be attempting to create a mental image.

These findings are also really interesting in regard to memory and aphantasia, said Dr Rebecca Keogh, Postdoctoral research fellow based at Macquarie University and another author of the study. Our previous work has shown that aphantasic individuals are able to perform visual working memory tasks, remembering many images for a short period of time, without using visual imagery.

These findings further highlight the wide variability of the human mind that can often remain hidden until we ask someone about their internal experiences or invent new ways to measure the mind. It reminds us that just because I remember or visualise something one way, doesnt mean everyone does.

Whats next for aphantasia research? A look into the future

Next, Prof Pearson and his team at the Future Minds Lab plan to investigate how this new method could be scaled up and run online to allow a global, efficient and objective measurement of imagery and aphantasia.

This really is an exciting time. We are very close to having objective, reliable tests for extreme imagery, aphantasia and hyperphantasia (extremely strong visual imagery) that could be scaled up to run online for millions of people everywhere, says Prof Pearson.

We know that thinking in pictures or not affects the number of details in lifelong memories, how emotional we get when reading, and how we hold things in short term memory. This new method will allow us to understand the brain mechanisms of extreme imagery and the global implications for how we think, make decisions and feel.

Author: Jesse HawleySource: University of New South WalesContact: Jesse Hawley University of New South WalesImage: The image is in the public domain

Original Research: Open access.The pupillary light response as a physiological index of aphantasia, sensory and phenomenological imagery strength by Joel Pearson et al. eLife

Abstract

The pupillary light response as a physiological index of aphantasia, sensory and phenomenological imagery strength

The pupillary light response is an important automatic physiological response which optimizes light reaching the retina.

Recent work has shown that the pupil also adjusts in response to illusory brightness and a range of cognitive functions, however, it remains unclear what exactly drives these endogenous changes.

Here, we show that the imagery pupillary light response correlates with objective measures of sensory imagery strength. Further, the trial-by-trial phenomenological vividness of visual imagery is tracked by the imagery pupillary light response.

We also demonstrated that a group of individuals without visual imagery (aphantasia) do not show any significant evidence of an imagery pupillary light response, however they do show perceptual pupil light responses and pupil dilation with larger cognitive load.

Our results provide evidence that the pupillary light response indexes the sensory strength of visual imagery. This work also provides the first physiological validation of aphantasia.

Link:
Windows to the Soul: Pupils Reveal Aphantasia The Absence of Visual Imagination - Neuroscience News

BetterLife To Present BETR-001 Preclinical Data at the Upcoming Canadian Association for Neuroscience Conference – Yahoo Finance

BetterLife Pharma Inc.

VANCOUVER, British Columbia, April 21, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (BetterLife or the Company) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that an abstract on the preclinical data on anti-depressant activity of its lead compound 2-bromo-LSD (BETR-001) was accepted for presentation at the upcoming Canadian Association for Neuroscience (CAN) Conference, being held May 12-15 in Toronto, Canada. The study, led by Dr. Vern Lewis, is part of BetterLifes collaboration with the laboratory of Dr. Argel Aguilar-Valles at Carleton Universitys Department of Neuroscience. This collaboration is also supported by the Mitacs Accelerate program.

At CAN, Dr. Lewis will present preclinical data demonstrating the neural plasticity-promoting and anti-depressant properties of BETR-001 from both in vitro and in vivo studies. The Dr. Lewis study demonstrated that treatment of rat embryonic cortical neurons with BETR-001 increases the structural complexity of neurons (dendrite growth and complexity) and therefore, provides evidence of neural plasticity activity of BETR-001. In certain measurements of structural plasticity in neurons, BETR-001 performed better than ketamine in this model.

BetterLife believes that BETR-001 is an uniquely positioned LSD derivative with the potential to be as effective as LSD in various neuro-psychiatric and neurological disorders without the burden of being hallucinogenic. Because of its non-hallucinogenic nature, BETR-001 will not have all the LSD requirements of administration in specialized clinics under special treatment protocols, the LSD controlled substance regulatory issues which impact manufacturing, distribution and patient access, and the overall associated high treatment costs for all these parameters. BETR-001 is protected by BetterLifes composition, method-of-use, synthesis and formulation patents (issued & provisional).

About BetterLife Pharma

Story continues

BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders.

BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLifes synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent for composition and method of use covers treatment of depression, cluster headaches, post-traumatic stress disorder and other neuro-psychiatric and neurological disorders.

BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLifes pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency.

BetterLife also owns a drug candidate for the treatment of viral infections such as COVID-19 and is in the process of seeking strategic alternatives for further development.

For further information, please visit BetterLife Pharma.

About the Department of Neuroscience at Carleton University

Carleton Neuroscience has an international reputation for research on stress and its effects on brain functioning and mental health. The department has an interdisciplinary approach to understanding the emergence, prevention and treatment of mental and physical disorders.For more information, please visit http://www.carleton.ca/neuroscience.

Contact Information

David Melles, Investor Relations ManagerEmail: David.Melles@blifepharma.comPhone: 1-778-887-1928

Cautionary Note Regarding Forward-Looking Statements

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as will, may, should, anticipate, expects and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Companys expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

View original post here:
BetterLife To Present BETR-001 Preclinical Data at the Upcoming Canadian Association for Neuroscience Conference - Yahoo Finance

Drug Reduced Frequency of Breathing Pauses in Sleep Apnea – Neuroscience News

Summary: Sulthiame, a CA inhibitor drug, reduced the number of breathing pauses and promoted oxygenation during the night in sufferers of obstructive sleep apnea.

Source: University of Gothenburg

A new University of Gothenburg study has paved the way for the first drug treatment for sleep apnea. Compared to before receiving the treatment, breathing pauses decreased with on average more than 20 per hour for patients given the drug.

The treatment that has been tested is carbonic anhydrase (CA) inhibition, CA being an enzyme that serves to maintain a balance between carbonic acid and carbon dioxide in the body. Several drugs with CA inhibitory properties are already available on the market, and used for treatment of glaucoma, epilepsy and other disorders.

Previous research has not systematically tested whether CA inhibitors also might be used to treat obstructive sleep apnea. The current study was a randomized double-blind clinical trial, and 59 patients with moderate or severe sleep apnea completed it.

Patients were randomly assigned to two groups receiving either 400 or 200 mg of the CA inhibitor, and a third group (the control group) that received placebo. The study lasted for four weeks.

Fewer breathing pauses

The results show that, overall, the treatment reduced the number of breathing pauses and promoted oxygenation during the night. A few patients experienced side effects, such as headache and breathlessness, which were more common in those receiving the highest dose.

The study results together with established safety data of the drug sulthiame provide support for continued research on CA inhibition as a new potential treatment for obstructive sleep apnea.

Among the patients who received the higher dosage of the drug, the number of breathing pauses decreased by approximately 20 per hour. For just over a third of patients in the study, only half of their breathing pauses were left, and in one in five the number fell by at least 60 percent, says Jan Hedner, Professor of Pulmonary Medicine.

The fact that several approved drugs in the CA inhibitor category are available on the market makes fast-tracking development of an approved drug for sleep apnea practicable. The drug used in this clinical trial was sulthiame, which is sometimes used to treat epilepsy in children.

Treatment options needed

Today, treatment for a patient with sleep apnea is either an oral appliance therapy or a CPAP (Continuous Positive Airway Pressure) mask. Both help to maintain airway patency during sleep.

These therapy options take time to get used to and, since they frequently are perceived as intrusive or bulky. Insufficient user time is therefore common. If we develop an effective drug, it will therefore make life easier for many patients and, in the long run, potentially also save more lives, says Ludger Grote, Senior Lecturer at Sahlgrenska Academy, University of Gothenburg.

The German pharmaceutical company Desitin Arzneimittel GmbH funded the trial, and the results are published in the American Journal of Respiratory and Critical Care Medicine.

Author: Press OfficeSource: University of GothenburgContact: Press Office University of GothenburgImage: The image is in the public domain

Original Research: The findings will appear in American Journal of Respiratory and Critical Care Medicine

Visit link:
Drug Reduced Frequency of Breathing Pauses in Sleep Apnea - Neuroscience News

Treating, preventing cancer beyond genetics: U of A researcher – Edmonton Journal

Breadcrumb Trail Links

If we understand the causes of cancer, then we can start highlighting the known causes, the lifestyle issues that introduce or increase our risk

Environmental and metabolic factors not just genetics are growing considerations in the fight against cancer, concludes a research review by a leading expert at the University of Alberta.

This advertisement has not loaded yet, but your article continues below.

Cancer as a genetic disease, focusing on the set of genetic instructions every person is born with; it is also an environmental disease, focusing on the exposome, which includes everything a persons body has been exposed to; and cancer is a metabolic disease, focusing on the metabolome, or all the chemical byproducts of the process of metabolism, explains David Wishart, professor in the departments of biological sciences and computing science, in a Thursday news release.

But that metabolic perspective hasnt had much research until now, as more scientists begin to understand the metabolomes role in cancer.

Heritable cancers account for just five to 10 per cent of all cancers, Wishart said, with the other 90 to 95 per cent initiated by factors in the exposome, which in turn trigger genetic mutations.

This advertisement has not loaded yet, but your article continues below.

Thats an important thing to consider, because it says that cancer isnt inevitable.

As cancer develops and spreads in the body, it creates its own environment and introduces certain metabolites, becoming a self-fuelled disease. And thats where cancer as a metabolic disorder becomes really important.

Considering the genome, exposome and metabolome together when thinking about cancer shows more promise for finding treatments.

Researchers who focus only on the genetic perspective are looking to address particular mutations but there are around 1,000 genes that can become cancerous when mutated, and it typically takes two different mutations within these cells for cancer to grow, notes Wishart, meaning there are a million potential mutation pairs. Then it can become hopeless to narrow down possibilities when seeking new treatments.

This advertisement has not loaded yet, but your article continues below.

But considering cancer from the metabolic perspective, there are just four major metabolic types, said Wishart, so determining the patients cancer type can immediately guide doctors on the best treatment for their specific cancer.

It really doesnt make a difference where the cancer is its something youve got to get rid of. Its how it thrives or grows that matters, said Wishart. It becomes a question of, Whats the fuel that powers this engine?

Wishart cautions that health-care providers still need a mix of therapeutics for cancer, and a deeper understanding of the metabolome and its role in the cancer feedback loop is also critical to preventing cancer.

If we understand the causes of cancer, then we can start highlighting the known causes, the lifestyle issues that introduce or increase our risk, he said.

From the prevention side, changing our metabolism through lifestyle adjustments will make a huge difference in the incidence of cancer.

The research review was funded by Genome Canada, the Canadian Institutes of Health Research and the Canada Foundation for Innovation.

This advertisement has not loaded yet, but your article continues below.

Sign up to receive daily headline news from the Edmonton Journal, a division of Postmedia Network Inc.

A welcome email is on its way. If you don't see it, please check your junk folder.

The next issue of Edmonton Journal Headline News will soon be in your inbox.

We encountered an issue signing you up. Please try again

Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notificationsyou will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

Link:
Treating, preventing cancer beyond genetics: U of A researcher - Edmonton Journal

Discovering Genetic Variants that Significantly Predispose People to Critical COVID-19 – News-Medical.Net

Please can you introduce yourself, tell us about your background in medical informatics, and what inspired your latest research into identifying independent variants that significantly predispose to critical COVID-19?

My name is Erola Pairo-Castineira, and I am a postdoctoral researcher specializing in statistical genetics in Professor Baillie's lab at the University of Edinburgh.

I'm interested in the differences in DNA sequence between people and how this affects how sick you get when infected with SARS-CoV-2. Most people are asymptomatic or have mild symptoms when infected, while some people need hospitalization and a few need to be admitted into ICU to receive mechanical ventilation. Although certain factors like age and sex affect your predisposition to critical COVID-19, there are differences even in people with similar age, sex, and other variables affecting COVID-19 severity.

Our research aims to find the genetic factors that may predisposeto critical COVID-19 and learn how COVID-19 affects cells in the body. The main objective of the project is to find which biological pathways influence critical COVID-19 to be able to find druggable targets that may benefit everyone.

People suffering from critical COVID-19 have been admitted into an intensive care unit. They will have all the classic symptoms of COVID-19, such as a cough and fever, but also very low blood oxygen. The mechanism causing it is inflammation in the lung, where the virus is replicating.

Image Credit: plo/Shutterstock.com

In our first study, we found five genetic signals related to critical COVID-19 related to host antiviral defense mechanisms and mediators of inflammatory organ damage. Other studies since then have found signals related to susceptibility to infection with SARS-CoV-2 and hospitalization and critical illness with COVID-19.

Microarray genotyping reads a set of variants in the genome, and from them, and using information about genomes of known populations, we infer the rest of the genome. This is very difficult to do for rare variants, which will have low accuracy in the inference, and it is also affected by the quality of the reference panel used. Even in the best cases, not all variants can be retrieved with high accuracy, and some of them have to be filtered. Whole-genome sequencing reads every base in our genome, providing high accuracy for all variants.

To carry out the analysis, we compared the genome of people who had critical COVID-19, focusing on people in intensive care units in UK hospitals, with individuals that had only mild symptoms during SARS-CoV-2 infection, and with the general population. The comparison highlights variants of the genome that affect your probability of becoming critically ill with COVID-19.

In this study, we found 16 new regions associated with critical COVID-19. We were also able to identify some of these variants as variants that affect the function of some proteins (for example, a protein called IFNA10). In other cases, we could show that changes in gene expression would affect the probability of having severe COVID-19.

Interferons are a large family of proteins with roles in antiviral defense. They are produced when the cell recognizes a viral intruder, and they propagate defensive and offensive signals to help destroy the virus and protect nearby cells. Interferons can induce inflammation by activating the transcription of a number of different genes, and if they are not tightly controlled during an immune reaction, they may cause hyper-inflammation.

There are different types of interferon, called Interferon Type-I, Interferon Type-II, and Interferon Type-III. The genes we have found are mainly associated with Type-I Interferon signaling. Interestingly, one of these genes (TYK2) has a protein product that a widely available drug, baricitinib, can inhibit. It was recently shown in the RECOVERY trial (a large-scale randomized control trial for many potential COVID-19 treatments in the UK) that administration of baricitinib can lower mortality in COVID-19.

Image Credit: Thanapipat Kulmuangdoan/Shutterstock.com

In the case of baricitinib, it was lucky that it was already available for rheumatoid arthritis, so it had been proven safe and effective. Usually, the process is much longer when a potential gene target is identified. The most important first step is confirming the associations we see in the DNA data in cells and tissues - in vitro experiments will be required to ensure the target is worth pursuing. An appropriate drug must be identified, tested, and shown to be safe. It can be a long process; however, our analysis can narrow down the most likely drug targets, which is a major step forward.

The study's main limitation is that we recruited cases in the middle of a pandemic, so we didn't have genotypes for mild cases to use as controls. Instead of mild COVID-19 cases, we used controls from different studies of the general population. This was technically challenging since the genotyping or whole-genome sequencing tools used differed, and we had to account for these differences. We now have genotypes from mild COVID-19 cases generated using the same pipelines as our critical COVID-19 cases.

Collaboration is vital to this research. People with very different expertise are needed to do an analysis like this. To carry out this analysis, we needed people to work in many different roles. Administrative staff organized paperwork and established sites, doctors and nurses recruited patients, research technicians sequenced DNA, then informaticians processed this DNA information in a computer and analyzed it to find the DNA regions related to COVID-19. Finally, it's rarely true that the results immediately make sense, so there were a number of groups of researchers working closely together to interpret the biological meaning of the results.

We're still working on critical COVID-19. We have recruited more individuals and will soon start a new analysis with 15,000 critical cases and 15,000 mild controls (people who had mild or asymptomatic COVID-19). We also have gene expression data from hospitalized patients that we can link to our analysis outputs which will likely help us address some of the limitations mentioned above.

My name is Erola Pairo-Castineira I am currently a postdoctoral researcher at the Roslin Institute at the University of Edinburgh. Over the last two years, I have been working on host genetic studies of COVID-19. I have conducted several analyses that have led to the discovery of new genetic associations of COVID-19 critical illness. Before my current position, I was a postdoctoral researcher in the MRC-HGU, working on the integration of omics and genotype data to identify causal genes and pathways underlying pigmentation traits.

Read this article:
Discovering Genetic Variants that Significantly Predispose People to Critical COVID-19 - News-Medical.Net

Study mines cancer genetics to help with targeted treatment – ABC News

Scientists from the United Kingdom have analyzed the full genetic blueprints of more than 18,000 cancer samples, finding new patterns of mutations that could help doctors provide better, more personalized treatment

By LAURA UNGAR AP Science Writer

April 21, 2022, 6:02 PM

3 min read

Scientists have analyzed the full genetic blueprints of more than 18,000 cancer samples, finding new patterns of mutations that could help doctors provide better, more personalized treatment.

Their study, published Thursday in the journal Science, isnt the first to do such comprehensive whole genome analyses of cancer samples. But no one has ever done so many.

This is the largest cohort in the world. It is extraordinary, said Serena Nik-Zainal of the University of Cambridge, who was part of the team.

Just over 12,200 surgical specimens came from patients recruited from the U.K. National Health Service as part of a project to study whole genomes from people with common cancers and rare diseases. The rest came from existing cancer data sets.

Researchers were able to analyze such a large number because of the same improvements in genetic sequencing technology that recently allowed scientists to finally finish decoding the entire human genome more capable, accurate machines.

We can really begin to tease out the underpinnings of the erosive sort of forces that go to sort of generate cancer," said Andrew Futreal, a genomic medicine expert at MD Anderson Cancer Center in Houston who was not involved in the study.

Cancer is a disease of the genome, or full set of instructions for running cells, that occurs when changes in a persons DNA cause cells to grow and divide uncontrollably. In 2020, there were about 19 million new cancer cases worldwide.

For the study, researchers looked at 19 different types breast, colorectal, prostate, brain and others and identified 58 new clues to the causes of cancer called mutational signatures" that contribute to the development of the disease. They also confirmed 51 of more than 70 previously reported mutation patterns, Nik-Zainal said.

Some arise because of problems within a persons cells; others are sparked by environmental exposures such as ultraviolet radiation, tobacco smoke or chemicals.

Knowing more of them helps us to understand each persons cancer more precisely, which can help guide treatment, Nik-Zainal said.

Genetic sequencing is already being woven into cancer care as part of the growing trend of personalized medicine, or care based on a patients genes and specific disease. Now doctors will have much more information to draw from when they look at individual cancers.

To help doctors use this information, researchers developed a computer algorithm that will allow them to find common mutation patterns and seek out rare ones. Based on a particular pattern, Nik-Zainal said a doctor may suggest a certain course of action, such as getting immunotherapy.

Futreal said the data can also show doctors what tends to happen over time when a patient develops a cancer with a certain mutation pattern helping them intervene earlier and hopefully stop the developing disease in its tracks.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institutes Department of Science Education. The AP is solely responsible for all content.

Read the rest here:
Study mines cancer genetics to help with targeted treatment - ABC News